Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Sarcoma, Myeloid 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1

Interventions

Cytarabine 272Cyclophosphamide 136fludarabine phosphate 127Azacitidine 117Peripheral Blood Stem Cell Transplantation 95Busulfan 93Filgrastim 80fludarabine 78Mycophenolic Acid 78Decitabine 78Idarubicin 76Etoposide 76Whole-Body Irradiation 75Daunorubicin 72Tacrolimus 71Cyclosporine 64Methotrexate 62Mitoxantrone 57Clofarabine 55Antilymphocyte Serum 55Granulocyte Colony-Stimulating Factor 51Gemtuzumab 50Melphalan 49venetoclax 47Radiotherapy 30sargramostim 28Bortezomib 25thymoglobulin 24aldesleukin 24Injections 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Leukemia, Myeloid, Acute × Leyk × Clear all
NCT01371981 2026-06-02

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
1,645 enrolled 32 charts
Other hematologic neoplasmSarcoma

Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡